New research shows 92% of cancer patients stayed cancer-free for two years after immune-based therapy, potentially avoiding ...

The AACR meeting was full of promising data on the vaccine against cervical cancer, a lung cancer drug and the next ...

We are navigating political interference, institutional instability, and growing uncertainty across the cancer research ...

According to the results of the early study, published simultaneously in the New England Journal of Medicine, 92% of patients ...

For a limited group of cancer patients who have solid tumors in the stomach, rectum, esophagus and other organs, an ...

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and ...

Immunotherapy let some cancer patients with mismatch repair deficient tumors completely avoid surgery, chemo and radiation, a ...

Adding pembrolizumab (Keytruda), before and after surgery, to standard adjuvant therapy for locally advanced head and neck ...

A new, small cancer study may give hope to patients with solid tumors in the stomach, esophagus or rectum. The standard ...

The FDA is currently reviewing Merck’s sBLA for Keytruda in head and neck cancer, with a target action date of June 23.

The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain ...